Australia markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
39.28+0.79 (+2.07%)
As of 11:24AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close38.49
Open38.50
Bid39.88 x 800
Ask39.80 x 1800
Day's range38.11 - 40.58
52-week range13.84 - 62.49
Volume591,784
Avg. volume2,342,612
Market cap1.64B
Beta (5Y monthly)0.03
PE ratio (TTM)N/A
EPS (TTM)-1.16
Earnings date27 Feb 2023 - 03 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Dec 2012
1y target est69.75
  • GlobeNewswire

    Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

    Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzhe

  • GlobeNewswire

    Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

    AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. JonesTrading

  • GlobeNewswire

    Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

    AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offer